October 17, 2022 from 6:45 am – 7:45 am CDT
Supported by an independent educational grant from United Therapeutics Corporation.
Program Description
Interstitial Lung Disease is a broad term encompassing more than 200 diverse and distinct diseases characterized by inflammation or fibrosis of the pulmonary parenchyma, with reduction in pulmonary function. ILD symptoms are insidious and nonspecific, and despite the availability of diagnostic criteria and published resources, clinicians are challenged to correctly identify ILD in a timely manner. Furthermore, pulmonary hypertension (PH) is a complication of ILD, which is associated with decreased survival. Because progressive ILDs and associated comorbidities cause high mortality rates, the early and accurate identification of ILD is critical to achieve the best possible outcomes for patients.
Join our panel of top experts for an interactive CME-certified symposium focused on the multidisciplinary care of patients with ILD, including strategies to identify PH-ILD early, and treatment options to improve patient outcomes.
Speakers
Oksana Shlobin, MD
Georgetown University School of Medicine
Associate Professor
Falls Church, VA
University of Virginia School of Medicine
Associate Professor
Falls Church, VA
Inova Fairfax Hospital
Pulmonary Hypertension ProgramDirector of Education, Advanced Lung Disease and Transplant Program
Medical Director
Falls Church, VA
Deborah J. Levine, MD
University of Texas Health Science Center at San Antonio
Professor of Medicine
San Antonio, TX
University of Texas Health Science Center at San Antonio
Lung Transplantation
Clinical Medical Director
San Antonio, TX
University of Texas Health Science Center at San Antonio
Pulmonary Hypertension Center
Director
Boston, MA
Ioana H. Preston, MD
Tufts University School of Medicine
Pulmonary Function Lab Director
Associate Professor
Boston, MA
Tufts University School of Medicine
Pulmonary Hypertension Center
Director
Boston, MA